BIRC5 and neoplasm: The data in our report show that NY-ESO-1 and survivin can now be added as a tumor-associated target for the biological treatment of patients with glioma, particularly since data from several NY-ESO-1-directed [45] or anti-survivin-directed trials did not report [46] major toxicity.